Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CVS HEALTH CORPORATION

(CVS)
  Report
Real-time Estimate Cboe BZX  -  11:59 2022-12-07 am EST
102.11 USD   +0.91%
10:46aAround 5.5 million people have signed up for 2023 Obamacare plans
RE
12/05MarketScreener's World Press Review: December 5, 2022
MS
12/05CVS Reportedly Testing Remote Prescription System
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS Health : Says Covid-19 Test Delays Are Abating -- 3rd Update

08/05/2020 | 03:22pm EST

By Sharon Terlep

CVS Health Corp. said delays getting Covid-19 test results to customers are abating after backlogs led to extended wait-times that threatened to hamper efforts to contain the coronavirus pandemic.

The drugstore giant, the biggest retail chain conducting Covid-19 tests in the U.S., said it temporarily reduced the amount of new tests it administered while adding additional labs to process backlogged results. CVS didn't quantify the improvement in wait times.

CEO Larry Merlo said in an interview on Wednesday that wait times have vastly improved, though one of four labs CVS contracts with to process results is still experiencing significant delays. He declined to name the lab and said that, within a week or so, all results for tests administered by CVS should be available in three to four days.

For much of July, people getting Covid-19 tests at CVS faced weekslong wait times for results that were supposed to be available within days. Some customers have said they continue to wait weeks for their results. CVS has said delays at laboratories CVS contracts with to process results caused the slowdown.

Prolonged wait times for test results can complicate efforts to find and isolate people with whom an infected individual had contact.

"We want to make sure any ramp up doesn't undo the progress we've made in the turnaround times," Mr. Merlo said.

He said the company increased testing under guidance from state health officials.

The company is working to ramp up testing as the nation's diagnostic capacity remains well short of what health experts recommend to contain the virus. Mr. Merlo said CVS is administering roughly 40,000 tests a day, or 1.2 million a month, among roughly 17 million tests that are administered monthly in the U.S.

As it works to further build up Covid testing, CVS is readying for higher-than-normal demand for flu vaccines this season. Vaccinating against the flu will have heightened importance, Mr. Merlo said, because flu and Covid share similar symptoms.

CVS on Wednesday also disclosed financial results for the latest quarter, saying that profits in its insurance business were bolstered as Americans held off on elective procedures and regular health care amid the pandemic.

Shares were down 1.5% in afternoon trading.

CVS, which owns insurance giant Aetna, joins other insurers realizing savings from skipped elective procedures and reduced visits to clinics and emergency rooms. Those savings have well eclipsed insurers' payouts for coronavirus care.

At the same time, CVS's store sales fell 4.5% and the number of prescriptions filled in the quarter fell 1.1%, as shelter-in-place orders kept people home.

The company said customers are returning to more normal health-care routines now and that it expects more people will use their insurance for health care in the second half of the year.

The pharmacy chain said it now expects earnings of $5.59 to $5.72 a share, or $7.14 to $7.27 a share on an adjusted basis. It previously expected earnings of $5.47 to $5.60 a share, or $7.04 to $7.17 a share on an adjusted basis.

CVS posted second-quarter profit of $2.98 billion, or $2.26 a share, compared with $1.94 billion, or $1.49 a share, in the same period last year. Adjusted earnings were $2.64 a share, ahead of the $1.91 a share analysts polled by FactSet had expected.

The Woonsocket, R.I.-based company reported sales of $65.34 billion.

Sales in the company's health-care-benefits segment, which includes Aetna, rose 6.1% to $18.47 billion. It reported a medical-loss ratio, or the share of premiums the insurer pays out in claims, of 70.3%.

Sales in the company's segment that fulfills medication prescriptions and sells general products rose 1% to $21.66 billion. Pharmacy-services segment sales rose slightly to $34.89 billion, partially offset by lower provider visits during the quarter.

--Dave Sebastian contributed to this article.

Write to Sharon Terlep at sharon.terlep@wsj.com

 

All news about CVS HEALTH CORPORATION
10:46aAround 5.5 million people have signed up for 2023 Obamacare plans
RE
12/05MarketScreener's World Press Review: December 5, 202..
MS
12/05CVS Reportedly Testing Remote Prescription System
MT
12/05North American Morning Briefing: Fed Tightening Fears to..
DJ
12/02bswift appoints Ted Bloomberg as New Chief Executive Officer
AQ
12/01CVS Health Opens MinuteClinic Locations in Delaware
PR
12/01CVS Health Opens Minuteclinic Locations in Delaware
CI
11/30Cvs Health : completes rollout of time delay safes in 13 states
PU
11/28North American Morning Briefing: Covid Protests in China Spread, Hit Market Se..
DJ
11/23Morgan Stanley Adjusts Price Target on CVS Health to $119 From $124, Assumes Overweight..
MT
More news
Analyst Recommendations on CVS HEALTH CORPORATION
More recommendations
Financials (USD)
Sales 2022 314 B - -
Net income 2022 4 597 M - -
Net Debt 2022 40 593 M - -
P/E ratio 2022 31,0x
Yield 2022 2,15%
Capitalization 133 B 133 B -
EV / Sales 2022 0,55x
EV / Sales 2023 0,51x
Nbr of Employees 258 000
Free-Float 74,5%
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 101,19 $
Average target price 118,61 $
Spread / Average Target 17,2%
EPS Revisions
Managers and Directors
Karen S. Lynch President, Chief Executive Officer & Director
Shawn M. Guertin Chief Financial Officer & Executive Vice President
Roger N. Farah Chairman
Sreekanth Chaguturu Chief Medical Officer & Executive Vice President
Tilak Mandadi EVP, Chief Data, Digital & Technology Officer